2014 Annual Meeting | 4ES.001 - The Intractable Headache Patient

Date Tuesday 04/29/14

Time 02:00 PM - 05:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Extended Seminar

Director(s) Charles C. Flippen II, MD, FAAN

Topic(s)

Learning Objectives Participants should be able to recognize and treat medication overuse headache, including using proper detoxification strategies, employing specific outpatient and inpatient treatment strategies for the difficult-to-treat headache patient, having the clinical skills to treat patients with intractable migraine headaches, and understanding when the use of adjunctive interventional methods advance the patients care .

CME Available No CME available

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic

Event Timeline
02:00 PM - 02:50 PM		Evaluation of the Intractable Headache Patient Charles C. Flippen II, MD, FAAN
02:55 PM - 03:45 PM		Interventional Techniques for the Intractable Headache Patient - Nerve Blockade Morris Levin, MD, FAAN
03:45 PM - 04:00 PM		Break
04:00 PM - 04:45 PM		Interventional Therapies to Aid the Intractable Headache Patient Abraham A. Ashkenazi, MD
04:45 PM - 05:00 PM		Questions and Answers

Faculty Disclosures
Charles C. Flippen II, MD, FAAN	Dr. Flippen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Carelon. Dr. Flippen has a non-compensated relationship as a committee member with American Headache Society that is relevant to AAN interests or activities. Dr. Flippen has a non-compensated relationship as a committee/task force member with American Neurological Association that is relevant to AAN interests or activities.
Morris Levin, MD, FAAN	Dr. Levin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus, Upsher Smith, Biohaven, Revance, Percept, Theranica, Allergan, Alder, Currax. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Attorney . Dr. Levin has received stock or an ownership interest from Percept. Dr. Levin has received publishing royalties from a publication relating to health care.
Abraham A. Ashkenazi, MD	No disclosure on file